MedTrace Logo

The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes

NCT00044148 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2017-02-01

No results posted yet for this study

Summary

The purpose of this study are to determine 1) Whether Ly333531 can reduce urinary albumin/creatinine excretion in patients with Type II diabetes and persistent albuminuria 2) Whether LY333531 reduces urinary TGF-B, 3) the safety of LY333531 and any side effects that may be associated with it.

Conditions

  • Diabetic Nephropathy

Interventions

DRUG

LY333531

Sponsors & Collaborators

  • Chromaderm, Inc.

    lead INDUSTRY

Study Design

Purpose
TREATMENT

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2002-07-16
Primary Completion
2004-04-28
Completion
2004-04-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00044148 on ClinicalTrials.gov